Search Results - (Author, Cooperation:C. Finet)

Showing 1 - 3 results of 3, query time: 0.13s Refine Results
  1. 1
    J. A. Banks ; T. Nishiyama ; M. Hasebe ; J. L. Bowman ; M. Gribskov ; C. dePamphilis ; V. A. Albert ; N. Aono ; T. Aoyama ; B. A. Ambrose ; N. W. Ashton ; M. J. Axtell ; E. Barker ; M. S. Barker ; J. L. Bennetzen ; N. D. Bonawitz ; C. Chapple ; C. Cheng ; L. G. Correa ; M. Dacre ; J. DeBarry ; I. Dreyer ; M. Elias ; E. M. Engstrom ; M. Estelle ; L. Feng ; C. Finet ; S. K. Floyd ; W. B. Frommer ; T. Fujita ; L. Gramzow ; M. Gutensohn ; J. Harholt ; M. Hattori ; A. Heyl ; T. Hirai ; Y. Hiwatashi ; M. Ishikawa ; M. Iwata ; K. G. Karol ; B. Koehler ; U. Kolukisaoglu ; M. Kubo ; T. Kurata ; S. Lalonde ; K. Li ; Y. Li ; A. Litt ; E. Lyons ; G. Manning ; T. Maruyama ; T. P. Michael ; K. Mikami ; S. Miyazaki ; S. Morinaga ; T. Murata ; B. Mueller-Roeber ; D. R. Nelson ; M. Obara ; Y. Oguri ; R. G. Olmstead ; N. Onodera ; B. L. Petersen ; B. Pils ; M. Prigge ; S. A. Rensing ; D. M. Riano-Pachon ; A. W. Roberts ; Y. Sato ; H. V. Scheller ; B. Schulz ; C. Schulz ; E. V. Shakirov ; N. Shibagaki ; N. Shinohara ; D. E. Shippen ; I. Sorensen ; R. Sotooka ; N. Sugimoto ; M. Sugita ; N. Sumikawa ; M. Tanurdzic ; G. Theissen ; P. Ulvskov ; S. Wakazuki ; J. K. Weng ; W. W. Willats ; D. Wipf ; P. G. Wolf ; L. Yang ; A. D. Zimmer ; Q. Zhu ; T. Mitros ; U. Hellsten ; D. Loque ; R. Otillar ; A. Salamov ; J. Schmutz ; H. Shapiro ; E. Lindquist ; S. Lucas ; D. Rokhsar ; I. V. Grigoriev
    American Association for the Advancement of Science (AAAS)
    Published 2011
    Staff View
    Publication Date:
    2011-05-10
    Publisher:
    American Association for the Advancement of Science (AAAS)
    Print ISSN:
    0036-8075
    Electronic ISSN:
    1095-9203
    Topics:
    Biology
    Chemistry and Pharmacology
    Computer Science
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Angiosperms/chemistry/genetics ; *Biological Evolution ; Bryopsida/genetics ; Chlamydomonas/chemistry/genetics ; DNA Transposable Elements ; Evolution, Molecular ; Gene Expression Regulation, Plant ; Genes, Plant ; *Genome, Plant ; MicroRNAs/genetics ; Molecular Sequence Data ; Phylogeny ; Plant Proteins/genetics/metabolism ; Proteome/analysis ; RNA Editing ; RNA, Plant/genetics ; Repetitive Sequences, Nucleic Acid ; Selaginellaceae/*genetics/growth & development/metabolism ; Sequence Analysis, DNA
    Published by:
    Latest Papers from Table of Contents or Articles in Press
  2. 2
    Finet, C.
    Springer
    Published 1984
    Staff View
    ISSN:
    1432-1807
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Mathematics
    Type of Medium:
    Electronic Resource
    URL:
    Articles: DFG German National Licenses
  3. 3
    Staff View
    ISSN:
    1573-0646
    Keywords:
    idarubicin ; 4-demethoxydaunorubicin ; anthracycline ; anticancer agent ; phase I study
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Chemistry and Pharmacology
    Medicine
    Notes:
    Summary Thirty one patients with solid tumors were entered into a phase I trial with idarubicin, a new anthracycline antibiotic with oral antitumor activity in animals. The drug was scheduled to be given for 4 consecutive weeks at doses ranging from 10 to 20 mg/m2. Leukopenia was the dose-limiting toxicity. Thrombocytopenia was occasionally seen. Since several patients could not receive the third and fourth administrations of the drug at 17.5 and 20 mg/m2, higher doses were administered only for 2 consecutive weeks. With this schedule, the maximum tolerated dose was 25 mg/m2 and leukopenia was again the dose-limiting toxicity. With both schedules, myelosuppression was highly variable and could not be related to prior therapy, bone or liver metastases, or performance status. Other toxicities were mild to moderate and were dominated by nausea and vomiting which were observed in 29% of the patients. Alopecia and mucositis were unfrequent and cardiac toxicity was not observed. Starting doses of 15 mg/m2 for 4 consecutive weeks or 20 mg/m2 for 2 consecutive weeks could be proposed for oral phase II studies with idarubicin, under careful pharmacokinetic monitoring.
    Type of Medium:
    Electronic Resource
    URL:
    Articles: DFG German National Licenses